Tampere, Finland — 13 April 2026 — Vactech Oy today announced the release of a new educational video describing the scientific rationale behind PRV-101, Vactech’s investigational multivalent vaccine designed to prevent Coxsackievirus B infections and reduce the risk of type 1 diabetes (T1D).
Type 1 diabetes is an autoimmune disease in which insulin-producing beta cells are destroyed, leaving people dependent on lifelong insulin therapy. The new video summarizes evidence from large international studies linking Coxsackievirus B infections with the onset of T1D, and explains how early-life infection can reach the pancreas, infect beta cells, and contribute to inflammatory processes associated with beta-cell damage.
The video also introduces how PRV-101 is designed to work: it contains inactivated, non-infective Coxsackie B viruses which induce the production of neutralizing antibodies that can block viral entry into cells and clear the virus before it can spread to the pancreas.
“Vactech’s decision to take the next step in the PRV-101 program is based on strong scientific evidence on the role of Coxsackie B viruses in T1D and the ability of PRV-101 to induce protective antibodies against these viruses. This is a crucial part of our mission to develop prevention for T1D,” says Professor Heikki Hyöty, Founder and Chairman of the Board of Vactech.
“At Vactech, we are committed to leading the development of innovative vaccines. By preventing Coxsackievirus B infection, we have a unique opportunity to improve global health by reducing the incidence of type 1 diabetes and CVB-related diseases worldwide,” says Tero Välimaa, Ph.D., Chief Executive Officer.
Vactech is advancing PRV-101 toward its next clinical milestone, following successful completion of a Phase 1a clinical study and ongoing preparations for Phase 1b, including initiation of clinical trial material manufacturing.
Watch the video
Video link: https://youtu.be/NRMSaOOCO60
About Vactech
Vactech Oy is a biotechnology company specializing in the research and development of innovative vaccines and medical solutions. The company is developing vaccine and diagnostic technologies targeting type 1 diabetes, celiac disease, and enterovirus-related conditions.